Ventricular Tachycardia Ablation Guidance Includes Randomized Studies
This article was originally published in The Gray Sheet
Executive Summary
Randomized clinical studies remain an option for sponsors seeking approval of ablation devices for the treatment of ventricular tachycardia (VT), FDA's Center for Devices and Radiological Health says in a recent guidance.
You may also be interested in...
Randomized Controlled Trials May Be Less Burdensome, FDA Guidance Says
Randomized controlled clinical trials of medical devices represent, in certain circumstances, the least burdensome route for sponsors to gain FDA approval, the agency maintains.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”